molecules of the month

March 2020

With the all the newsflow on drug re-purposing for the coronavirus, it’s easy to overlook all the interesting drug discovery articles that have been published in March. A summary of some of the most interesting compounds that appeared online this month appears below, and links to the original articles are at the bottom. Two molecules with degrader mechanisms that demonstrated compelling in vivo activity made this month’s list, and a flurry of excellent molecules intended for hot (or once hot) oncology targets appeared as well.

nominate a molecule

Encountered an interesting new molecule? Let your community know!

become a reviewer

Get sneak previews of upcoming molecules and share your knowledge and expertise with the drug discovery community.

past molecules of the month

Check out previous selections below.

molecules of the year nominees

Previous selections for Drug Hunter’s Molecule of the Year below.

hall of fame
molecules of the year

Previous selections for Drug Hunter’s Molecule of the Year below.

RECENT ARTICLES

DRUG DISCOVERY RESOURCES

JOIN SUBSCRIBERS from

  • Johnson & Johnson
  • Roche
  • Pfizer
  • Novartis
  • Bayer
  • Merck
  • Sanofi
  • GlaxoSmithKline
  • AbbVie
  • Eli Lilly
  • Boehringer Ingelheim
  • Amgen
  • Bristol-Myers Squibb
  • Gilead
  • AstraZeneca
  • Teva
  • Novo Nordisk
  • Merck KGaA
  • Takeda
  • Celgene (BMS)
  • Biogen
  • Astellas
  • Daiichi Sankyo
  • Regeneron
  • UCB
  • Eisai
  • Servier
  • Kyowa Kirin
  • Shionogi
  • Vertex
  • Lundbeck
  • Taisho
  • Ono
  • Seagen
  • Incyte
  • LEO Pharma
  • Janssen
  • Galapagos
  • Idorsia
  • Astex
  • Arvinas
  • Kymera
  • Relay
  • Schrodinger
  • Mirati
  • Revolution
  • Nimbus
  • Plexxikon
  • Forma
  • Arcus
  • RA Capital
  • ARCH Venture Partners
  • MPM Capital
  • Orbimed
  • The Column Group
  • 5AM Ventures
  • Versant Ventures
  • Deerfield
  • Goldman Sachs
  • Citi
  • Piper Sandler
  • Softbank
  • …and hundreds of others